Research article
Cost-effectiveness analysis of antimuscarinics in the treatment of patients with overactive bladder in Spain: A decision-tree model
BMC Urology 2011, 11:9 doi:10.1186/1471-2490-11-9
Research article
- Welcome Stanford University
- Log on
mistake in figure 1
Javier Rejas (2011-06-21 16:49) Pfizer
In figure 1, there is a mistake in the decision tree for patients treated with tolterodine and solifenacin. It is written that all patients are treated at the end of the study period with fesoterodine 4 mg but there is a mistake. Patients who started treatment with tolterodine or solifenacin discontinued or remained with the same treatment until the end of the study, they do not switched to fesoterodine.
Competing interests
None declared
top